Dapagliflozin in Patients With CKD With Fabry Disease - PubMed
3 days ago
- #Fabry disease
- #SGLT2 inhibitors
- #Chronic kidney disease
- Dapagliflozin, an SGLT2 inhibitor, was studied in patients with Fabry disease (FD) and chronic kidney disease (CKD) to assess its effects on albuminuria, proteinuria, and renal function.
- The study included 16 adults with FD and albuminuric CKD, all on stable enzyme replacement therapy (ERT) or migalastat and maximally tolerated doses of renin-angiotensin system inhibitors (RAS-i).
- After 12 months of dapagliflozin treatment, significant reductions were observed in urinary albumin-to-creatinine ratio (UACR) by 47.6% and 24-hour proteinuria by 22.2%.
- Estimated glomerular filtration rate (eGFR) remained stable during dapagliflozin treatment, contrasting with a decline observed in the pre-treatment period.
- Eight out of nine fast renal progressor patients achieved an annual eGFR slope of ≤ 3 ml/min during the treatment period.
- The study concludes that dapagliflozin is associated with reduced albuminuria, proteinuria, and eGFR decline in FD patients with CKD over 12 months.